Scinai Immunotherapeutics Completes Acquisition of Recipharm Israel and Forms Strategic CDMO Partnership
核心洞察
Scinai Immunotherapeutics (搜索) has acquired 100% of Recipharm Israel Ltd. (搜索), which operates a cGMP manufacturing facility in Yavne, Israel, significantly expanding its contract development and manufacturing organization capabilities.
The acquisition includes a comprehensive commercial collaboration agreement with Recipharm that creates an integrated pathway for clients from early-stage development through commercial manufacturing.
The combined operations will now cover recombinant proteins (搜索), small molecules (搜索), peptides (搜索), antibodies (搜索), and oligonucleotides, addressing a key industry challenge of seamless program transitions between development stages.
Scinai Immunotherapeutics (搜索) Ltd. (NASDAQ: SCNI) has completed the acquisition of Recipharm Israel Ltd. (搜索) and entered into a strategic commercial collaboration with Recipharm, creating a differentiated end-to-end development and manufacturing platform that spans from early development through commercial supply.
The transaction significantly expands Scinai's manufacturing footprint and capabilities, strengthening its contract development and manufacturing organization (CDMO) platform. Under the collaboration agreement, development activities and tech transfer will be established between the companies to facilitate efficient graduation of Scinai clients to Recipharm at appropriate development stages.
Acquisition Details and Operational Integration
Scinai acquired 100% of the shares of Recipharm Israel Ltd. (搜索), which operates a cGMP manufacturing site in Yavne, Israel. The facility provides early chemistry development and small-scale manufacturing of active pharmaceutical ingredients (搜索) (APIs) for biopharmaceutical customers' clinical programs. The acquisition was structured as a share purchase to preserve full operational continuity, including employees, quality systems, regulatory approvals, customer contracts, and ongoing operations.
The Yavne facility comprises approximately 900 square meters of built area and includes multiple production rooms, analytical laboratories, an R&D laboratory, and controlled cleanroom environments. The site provides integrated capabilities spanning medicinal chemistry, route scouting and optimization, scale-up development, analytical method development and validation, stability studies, and small-batch cGMP manufacturing for toxicology and clinical studies.
Following closing, the Yavne site will continue to operate as part of Scinai's CDMO platform, complementing Scinai's existing Jerusalem-based capabilities in early-stage development, analytics, and clinical manufacturing. The financial terms of the Share Purchase Agreement remain confidential.
Strategic Commercial Collaboration Framework
Concurrently with the acquisition, Scinai and Recipharm entered into a comprehensive Commercial Collaboration Agreement designed to support customer projects across the full development lifecycle. The collaboration framework establishes that Scinai will serve as a preferred partner for early-stage development and clinical manufacturing projects within the Recipharm ecosystem, while Recipharm will serve as one of Scinai's preferred partners for late-stage clinical and commercial manufacturing.
Under the agreement, Scinai will have access to Recipharm's global manufacturing network under predefined commercial terms, providing the ability to support client programs that extend beyond the capabilities of Scinai's internal manufacturing footprint. The parties will mutually refer client projects and share economics as programs transition from early-stage development at Scinai to late-stage or commercial manufacturing at Recipharm.
The collaboration includes the establishment of a Master Quality Agreement and a Tech Transfer Framework Agreement, creating a pre-defined contractual basis for quality alignment, regulatory compliance, and efficient transfer of client programs across development stages.
Enhanced Capabilities and Market Positioning
As a result of the acquisition and collaboration agreement, Scinai's expanded capabilities will now cover recombinant proteins (搜索), small molecules (搜索), peptides (搜索), antibodies (搜索) and oligonucleotides through a combination of internal capabilities and collaboration with Recipharm. Key expected benefits include expanded support for small-molecule programs alongside peptides and liposomes, enhanced handling of complex and hazardous materials, and access to operating infrastructure and equipment that strengthen Scinai's industrial credibility, service breadth, and potential client base.
The Commercial Collaboration Agreement is intended to materially enhance Scinai's competitive positioning by expanding the breadth of service offerings through subcontracting selected capabilities from Recipharm under predefined commercial terms, while allowing Scinai to retain control over project management. The structure links Scinai's early-stage CDMO offering with Recipharm's global late-stage and commercial manufacturing footprint.
Addressing Industry Challenges
The collaboration addresses a common industry challenge faced by clients of smaller CDMOs: the risk of friction, delay, and cost overruns when programs transition to a global late-stage or commercial manufacturer. By pre-aligning quality systems, tech-transfer processes, and commercial incentives, the collaboration is designed to streamline these transitions and maintain continuity of service as client programs scale.
This positioning differentiates Scinai among smaller CDMOs by offering clients an integrated, end-to-end development pathway from early stage through commercialization. The collaboration also enables Scinai to participate economically in client programs that successfully progress to later-stage clinical supply or commercial manufacturing at Recipharm's facilities.
Management Perspectives
"This transaction fundamentally strengthens Scinai's CDMO platform," said Amir Reichman, Chief Executive Officer of Scinai. "By combining our early-stage development strengths with Recipharm Israel's manufacturing capabilities and Recipharm's global footprint, we are creating a differentiated offering that supports clients from early development through commercialization. Importantly, the collaboration allows Scinai to participate in the long-term success of client programs while maintaining capital discipline and operational focus."
Greg Behar, Chief Executive Officer of Recipharm, stated: "Ensuring continuity for the Yavne site, its employees and its customers was a key priority for us, and we are pleased to pair that with a strategic collaboration with Scinai. The agreement creates a clear pathway for programs to progress efficiently into Recipharm's global development and commercial manufacturing network."
Company Background
Scinai Immunotherapeutics (搜索) operates two complementary business units: Scinai Bioservices, a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services for biotech clients worldwide, and Scinai R&D, focused on developing innovative inflammation and immunology (搜索) therapeutics based on NanoAbs (VHH antibody fragments (搜索)).
Recipharm is a leading CDMO employing over 5,000 employees worldwide, providing expertise in development and manufacturing across oral dosage, sterile fill & finish and advanced biologics. The company operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US, manufacturing several hundred different products for customers ranging from big pharma to smaller research and development companies.